ceo-interviews 1933 Industries CEO Chris Rebentisch: Operational Changes Expected to Sustain Company During Downturn
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity